The histone acetyltransferase hMOF is overexpressed in non-small cell lung carcinoma

Korean Journal of Pathology

Volumn 45, Issue 4, 2011, Pages 386-396

  Song, Joon Seon ^a   Chun, Sung Min ^a   Lee, Ji Young ^a   Kim, Dong Kwan ^a   Kim, Yong Hee ^a   Jang, Se Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Acetylation; Carcinoma non small cell lung; Histone acetyltransferases; Histones

Indexed keywords

EID: 80052980935     PISSN: 17381843     EISSN: None     Source Type: Journal    
DOI: 10.4132/KoreanJPathol.2011.45.4.386     Document Type: Article

References (30)

1. Luger K, Mäder AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997; 389: 251-60.
2. Sims RJ 3rd, Nishioka K, Reinberg D. Histone lysine methylation: a signature for chromatin function. Trends Genet 2003; 19: 629-39.
3. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000; 403: 41-5.
4. Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 2001; 15: 2343-60.
5. Van Holde KE. Chromatin. New York: Springer, 1988.
6. Carrozza MJ, Utley RT, Workman JL, Côté J. The diverse functions of histone acetyltransferase complexes. Trends Genet 2003; 19: 321-9.
7. Eberharter A, Becker PB. Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep 2002; 3: 224-9.
8. Gayther SA, Batley SJ, Linger L, et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000; 24: 300-3.
9. Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005; 435: 1262-6.
10. Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000; 184: 1-16.
11. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005; 45: 495-528.
12. Munks RJ, Moore J, O'Neill LP, Turner BM. Histone H4 acetylation in Drosophila: frequency of acetylation at different sites defined by immunolabelling with site-specific antibodies. FEBS Lett 1991; 284: 245-8.
13. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37: 391-400.
14. Mendjan S, Taipale M, Kind J, et al. Nuclear pore components are involved in the transcriptional regulation of dosage compensation in Drosophila. Mol Cell 2006; 21: 811-23.
15. Smith ER, Cayrou C, Huang R, Lane WS, Côté J, Lucchesi JC. A human protein complex homologous to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16. Mol Cell Biol 2005; 25: 9175-88.
16. Taipale M, Rea S, Richter K, et al. hMOF histone acetyltransferase is required for histone H4 lysine 16 acetylation in mammalian cells. Mol Cell Biol 2005; 25: 6798-810.
17. Gupta A, Sharma GG, Young CS, et al. Involvement of human MOF in ATM function. Mol Cell Biol 2005; 25: 5292-305.
18. Sykes SM, Mellert HS, Holbert MA, et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 2006; 24: 841-51.
19. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer, 2010.
20. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. Pathology and genetics of tumors of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004.
21. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-7.
22. Livak KJ. ABI PRISM 7700 Sequence Detection System. User bulletin No. 2. Relative quantitation of gene expression. Foster City: PE Applied Biosystems, 1997.
23. Pfister S, Rea S, Taipale M, et al. The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Int J Cancer 2008; 122: 1207-13.
24. Brabletz T, Herrmann K, Jung A, Faller G, Kirchner T. Expression of nuclear beta-catenin and c-myc is correlated with tumor size but not with proliferative activity of colorectal adenomas. Am J Pathol 2000; 156: 865-70.
25. Gupta A, Guerin-Peyrou TG, Sharma GG, et al. The mammalian ortholog of Drosophila MOF that acetylates histone H4 lysine 16 is essential for embryogenesis and oncogenesis. Mol Cell Biol 2008; 28: 397-409.
26. Pruitt K, Zinn RL, Ohm JE, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet 2006; 2: e40.
27. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366-74.
28. Stein CA, Cohen JS. Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res 1988; 48: 2659-68.
29. Cioca DP, Aoki Y, Kiyosawa K. RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Ther 2003; 10: 125-33.
30. Yang G, Cai KQ, Thompson-Lanza JA, Bast RC Jr, Liu J. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem 2004; 279: 4339-45.